We chose this approach because recent published research has found that while higher Hb levels are associated with reduced complications, the higher ESA dose needed to achieve those Hb levels is associated with increased drug-related complications, including stroke and non-CVD mortality [14, 27–29]. This evidence concerns the gene GSTM1 and stroke disorder.